Cardiovascular Outcomes Trials

The observation that some traditional classes of glucose-lowering agents may have contributed to elevated CV risk prompted regulatory agencies to mandate that new diabetes drugs demonstrate CV safety in dedicated, long-term, placebo controlled CV outcome trials. Evidence from some recent cardiovascular outcome trials has shown improved CV outcomes over and above existing therapies for CV risk factor control.